Spinocerebellar Ataxia Type 4 Overview
Learn About Spinocerebellar Ataxia Type 4
View Main Condition: Movement Disorders
- Spinocerebellar ataxia 4
- SCA4
- Spinocerebellar ataxia autosomal dominant with sensory axonal neuropathy
- Spinocerebellar ataxia type 4
William M Handy, MD PC
. Dr. Handy is rated as a Distinguished provider by MediFind in the treatment of Spinocerebellar Ataxia Type 4. His top areas of expertise are Spinocerebellar Ataxia Type 12, Spinocerebellar Ataxia Type 15, Spinocerebellar Ataxia Type 8, and Spinocerebellar Ataxia Type 10.
The Regents Of The University Of California
Susan Perlman is a Neurologist in Los Angeles, California. Dr. Perlman is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia Type 4. Her top areas of expertise are Spinocerebellar Ataxia, Friedreich Ataxia, Drug Induced Dyskinesia, and Olivopontocerebellar Atrophy.
Matthis Synofzik practices in Tuebingen, Germany. Mr. Synofzik is rated as an Elite expert by MediFind in the treatment of Spinocerebellar Ataxia Type 4. His top areas of expertise are Drug Induced Dyskinesia, Frontotemporal Dementia, Acute Cerebellar Ataxia, Spinocerebellar Ataxia, and Deep Brain Stimulation.
Background: Spinocerebellar ataxia type 7 (SCA7) is a disease in which people have problems with coordination, balance, speech and vision. It is caused by a change in the ATXN7 gene. A mutation in this ATXN7 gene causes changes in eye cells, which can lead to vision loss. There is no cure for SCA7 but researchers are looking for possible treatments. Researchers need more information about SCA7. They want to c...
Summary: CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, in...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center